LT-540-717 is a potent FLT3 inhibitor with antiproliferative activity; it also inhibits several acquired FLT3 mutations, including FLT3-ITD/D835V, FLT3-ITD/F691L, FLT3-D835Y, and FLT3-D835V; it has potential as an anti-acute myeloid leukemia (AML) agent.